

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Shee

of 2

<i>Complete If Known</i>	
Application Number	TBA
Filing Date	September 8, 2003
First Named Inventor	Mark COOPER
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	003659.00029

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature	/Scott Long/	Date Considered	07/26/2006
--------------------	--------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	TBA
(use as many sheets as necessary)				Filing Date	September 8, 2003
				First Named Inventor	Mark COOPER
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	2	Attorney Docket Number	003659.00029

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
SL		Aberle, et al., "The counterion influence on cationic lipid-mediated transfection of plasmid DNA", Biochimica et Biophysica Acta, 1996, pages 281-283, Elsevier Science B.V.		
		Allison, et al., "Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization", Journal of Pharmaceutical Sciences, 2000, pages 682-691, vol. 89, no. 5, Wiley-Liss, Inc., & American Pharmaceutical Association.		
		Choi, et al., "Lactose-Poly (ethylene Glycol)-Grafted Poly-L-Lysine as Hepatoma Cell-Targeted Gene Carrier", Bioconjugate Chem., 1998, pages 708-718, vol. 9, American Chemical Society.		
		Cortesi, et al., "Effect of DNA Complexion and Freeze-Drying on the Physicochemical Characteristics of Cationic Liposomes", Antisense & Nucleic Drug Development, 2000, pages 205-215, vol. 10, Mary Ann Liebert, Inc.		
		Katayose, et al., "Remarkable Increase in Nuclease Resistance of Plasma DNA through Supramolecular Assembly with Poly (ethylene glycol)-Poly (L-lysine)", Journal of Pharmaceutical Sciences, 1998, vol. 87, no. 2, American Chemical Society and American Pharmaceutical Association.		
		Katayose, et al., "Water-Soluble Polyion Complex Associates of DNA and Poly (ethylene glycol)-Poly (L-lysine) Block Copolymer", Bioconjugate Chem., 1997, pages 702-707, American Chemical Society.		
		Kilcher, et al., "Influence of the DNA Complexation Medium on the Transfection Efficiency of Lipospermine/DNA Particles", Gene Therapy, 1998, pages 855-860, vol. 5, MacMillan Press LTD., Basingstoke, Great Britain.		
		Kwok, et al., "Strategies for Maintaining the Particle Size of Peptide DNA Condensates Following Freeze-Drying", International Journal of Pharmaceutics, 2000, pages 81-88, vol. 203, no. 1-2, Elsevier Science B.V.		
		Li, et al., "Lyophilization of Cationic Lipid-Protamine-DNA (LPD) Complexes", Journal of Pharmaceutical Sciences, 2000, pages 355-364, vol. 89, no. 3, Wiley-Liss, Inc., & American Pharmaceutical Association.		
		Noel, et al., "High Compacted DNA - Polymer Complexes Via New Polynorbornene Polycationic Latexes With Acetate Counterion", SCISEARCH Database, 2000, pages 8980-8983, vol. 16, no. 23, American Chemical Society, Washington, D.C.		
		Paxon, et al., "The Effect of Lyophilization on Plasmid DNA Activity", Pharmaceutical and Development Technology, 2000, pages 115-122, vol. 5, no. 1, Marcel Dekker, Inc.		
		Toncheva, et al., "Novel vectors for gene delivery formed by self-assembly of NDA with poly (L-lysine) grafted with hydrophilic polymers", Biochimica et Biophysica Acta, 1998, pages 354-368, Elsevier Science B.V.		
		Vinogradov, et al., "Self-Assembly of Polyamine-Poly (ethylene glycol) Copolymers with Phosphorothioate Oligonucleotides", Bioconjugate Chem., 1998, pages 805-812, vol. 9, American Chemical Society.		
		Serres, et al., "DNA Condensation and Transfection of Cells in Culture by a New Polynorbornane Polycationic Polymer", Langmuir 1999, pages 6956-6950, Vol. 15, American Chemical Society		
		Wagner, et al., "Direct Evidence for Counterion Release upon Cationic Lipid- DNA Condensation", Langmuir 2000, pages 303-306, Vol. 16, American Chemical Society		
V		Marschall, et al., "Transfer of YACs up to 2.3 Mb intact into human cells with polyethylenimine", Gene Therapy, 1999, pages 1634-1637, Vol. 6		

Examiner Signature	/Scott Long/	Date Considered	07/26/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw one through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.